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A B S T R A C T 
 
Background: Hepatitis B is a health problem with high endemic in Indonesia. Hepatitis B virus 
infection is transmitted parenterally, has a risk of liver cirrhosis and hepatocellular carcinoma. 
Detection and quantification of HBV DNA are markers of active HBV replication and determine 
treatment options for hepatitis B. Methods: compare log reduction of HBV DNA in patients 
treated with Telbivudine and Tenofovir. Results: There was no significant difference in HBV 
DNA levels between before and after Tenofovir treatment, namely 6 months follow-up (OR 95% 
CI = 5.41 [0.83 - 35.16], p = 0.0770) and 12 months (OR 95% CI = 5.39 [0.83 - 34.99], p = 0.0780). 
Telbivudine administration showed a significant difference in HBV DNA levels between before 
and after treatment at 6 months follow-up (OR 95% CI = 13.69 [4.53 - 41.40], p = 0.0001) and 12 
months (OR 95% CI = 13.69 [ 4.53 - 41.41], p = 0.0001). Comparison of Tenofovir and Telbivudine 
therapy showed no significant difference at 6 months follow-up (OR 95% CI = 0.44 [0.10 - 1.88], 
p = 0.2690) but significant at 12 months follow-up (OR 95% CI = 6.23). [1.39 - 27.97], p = 0.0170). 
Conclusion:  There was a significant difference between the administration of Telbivudine as 
a treatment for hepatitis B with lower serum HBV DNA levels compared with the administration 
of Tenofovir at 12-month follow-up therapy. 
 
Keywords:  Hepatitis B, Telbivudine, Tenofovir, HBV DNA levels 
 
 
Nasution MI, et al.  CRJIM 2 (1): May 2021 
 
                                                   CRJIM • Vol 02• Number 1 • May 2021                                    Page | 137 
I N T R O D U C T I O N  
 Hepatitis B threatens millions of people 
worldwide and has infected approximately 1.2 
million people in the United States and 2 billion 
people in the world, with about 240 million 
people living with chronic hepatitis B. Most 
people do not realize they have been infected. 
Approximately one million people die every 
year from chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma. [1,2] 
 Hepatitis B is a health problem with 
high endemicity in Indonesia. Currently it is 
estimated that there are 28 million Indonesians 
infected with Hepatitis B and C, 14 million of 
whom have the potential to become chronic, 
and of these, 1.4 million people have the 
potential to suffer from hepatocellular 
malignancies which will have a huge impact on 
the quality of life of a patient. [3] 
 Hepatitis B is a disease caused by 
infection with the hepatitis B virus (HBV), a 
double-stranded DNA virus from the 
hepadnaviridae family. HBV replicates in the 
liver and causes acute and chronic hepatitis. 
This disease is transmitted parenterally, can 
become chronic, and cause cirrhosis and 
hepatocellular carcinoma. HBV is primarily a 
blood-transmitted and sexually transmitted 
infection and is transmitted through 
percutaneous and mucosal exposure. [4, 5] 
 HBV DNA detection and quantification 
currently play an important role in the 
diagnosis of infection, making therapeutic 
decisions, and the assessment of response to 
therapy. The presence of HBV DNA in peripheral 
blood is a reliable marker for active HBV 
replication. HBV DNA levels also determine 
treatment options for hepatitis B, using either 
IFN-a, nucleoside analogues, or nucleotide 
analogues. [6] 
 Therefore, this study will discuss the 
differences in Log HBV DNA after Telbivudin 
treatment compared with Tenofovir.  
M E T H O D S 
 This study is an analytical study with a 
prospective analytical observational approach 
conducted on patients undergoing treatment 
for hepatitis B infection using Telbivudine 
versus Tenofovir at the Gastroentero-
hepatology Department, Internal Medicine 
Section of the Saiful Anwar Hospital Malang and 
followed for two years from January 2016 to 
December 2017. The sample in this study were 
adult patients according to the inclusion 
criteria who had hepatitis B and signed an 
informed consent. Data collection was carried 
out at follow-up by means of anamnesis on the 
family and study subjects, physical 
examination and vital signs of the patient when 
he arrived at the Gastroenterohepatology Clinic 
room, quantitative HBV DNA measurement, and 
recording the results of patient supporting 
examinations such as SGOT and SGPT. 
 Data analysis required in this study is 
multiple logistic regression analysis to assess 
the comparison of Log HBV DNA between the 
Telbivudine and Tenofovir treatment groups in 
patients with hepatitis B with p value (<0.05). 
R E S U L T S  
 A total of 34 patients participated and 
were divided into the two treatment groups 
Tenofovir (n = 8, 48%) and Telbivudine (n = 26, 
52%). Patients were followed for two years from 
January 2016 to December 2017. The mean age 
of the subjects was 45.91 ± 15.27 years, with 
male (34.7%) and female (65.3%) sex. The mean 
age for the Tenofovir group was 41 ± 15.0 years 
and the mean age for the Telbivudine group 
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was 45.0 ± 13.0 years. The mean baseline 
levels of Tenofovir SGOT were 146 ± 337 IU / L 
and Sebivo 86 ± 95 IU / L, baseline HBV DNA 
Tenofovir 5.05 x 10 ^ 7 IU / mL and Sebivo 5.59 x 
10 ^ 6 IU / mL. With p-value (> 0.05) the entire 
study baseline was homogeneously 
distributed. It is shown at Table 1 below. 
Table 1. Subject Characteristic 
Characteristic 
Tenofovir 
(n = 8) 
Telbivudine 
(n = 26) 
p-
value 
Age (years) 41 ± 15 45 ± 13 0.4640 
Men 7 [87.5] 18 [69.2] 0.3240 
SGOT (IU/L) 146 ± 337 86 ± 95 0.4080 










Note: data were presented in mean ± SD or n[%]; SGOT, serum 
glutamic oxaloacetic transaminase; SGPT, serum glutamate-
pyruvate transaminase; HBV, hepatitis B virus; DNA, 
deoxyribonucleic acid 
  
The results (Table 2) of the p-value at 
baseline comparison with after treatment 
showed no significant difference between HBV 
DNA levels before and after Tenofovir 
treatment, both at 6-months follow-up (OR 95% 
CI = 5.41 [0.83 - 35.16], p = 0.0770) and 12 
months (OR 95% CI = 5.39 [0.83 - 34.99], p =  
0.0780). In contrast to Sebivo treatment, there 
was a significant difference between HBV DNA 
levels before and after Sebivo treatment, both 
at 6 months follow-up (OR 95% CI = 13.69 [4.53 
- 41.40], p = 0.0001) and 12 months (OR 95 % CI 
= 13.69 [4.53 - 41.41], p = 0.0001).  
 The results of multiple logistic 
regression analysis of serum HBV DNA levels 
between Telbivudine and Tenofovir in Table 3 
and Table 4 show that Telbivudine has a 
stronger association than Tenofovir. The mean 
± SD of Telbivudine at the 6-month follow-up 
treatment was 6912 ± 15176 and the 12-month 
follow-up was 2980 ± 7509.Then the mean ± SD 
of Tenofovir at the 6-month follow-up was 841 













value Mean SD N Mean SD n 
















                Note: Data are presented in mean ± SD; SD, standard deviation; n, sample size; OR, odd ratio; CI, confidence interval; HBV, hepatitis B virus;   
                             DNA, deoxyribonucleic acid. 
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The results of the p-value on the comparison 
of Tenofovir and after administration of 
Telbivudine showed that there was no 
significant difference in the 6-months follow-up 
comparison of Tenofovir and Telbivudine 
treatment (OR 95% CI = 0.44 [0.10 - 1.88], p = 
0.2690). However, striking results were seen 
after 12 months of follow-up, there was a 
significant difference in the 12-month follow-up 
comparison of the Tenofovir treatment with 
Telbivudine (OR 95% CI = 6.23 [1.39 - 27.97], p = 
0.0170). It is shown at Table 3. 
D I S C U S S I O N S  
 Hepatitis B is a liver infection caused by 
the hepatitis B virus. HBV DNA logs are said to 
have an association with treatment response, 
prognosis, and progression to malignancy in 
hepatitis B infection. HBV DNA level> 10,000 
copies / mL was a strong predictor of risk for 
developing hepatitis to HCC, and was an 
independent factor of HBeAg, serum ALT levels, 
and cirrhosis. Previous studies have suggested 
that Telbivudine and Tenofovir can lower the 
HBV DNA log in patients with Hepatitis B. [7] 
 The incidence of hepatitis B according 
to national surveillance data in Indonesia is 
quite high. Approximately 240 million 
individuals are chronically infected by Hepatitis 
B, and 75% are in Asia. The endemicity of 
Hepatitis B in Indonesia ranges from 2.5% to 
10% for hepatitis B surface antigen, and men 
are more infected than women, and the peak 
age of infection in adults is 19-45 years with 
increased risk factors for transmission in 
pregnant women, blood transfusion, and same-
sex. [8,9] 
 Tenofovir, a nucleotide analogue 
(nucleoside monophosphate), has strong 
activity against retroviruses and hepadna- 
viruses. The effect of Tenofovir treatment 
causes DNA chain breakdown, thereby 
preventing viral replication. [10,11] 
 Whereas Telbivudine is a synthetic 
thymidine nucleoside analogue with very 
specific antiviral activity for the treatment of 
hepatitis B virus (HBV), both for use alone or in 
combination with other agents in hepatitis B 
therapy. Di-deoxy telbivudine triphosphate 
competes with thymidine for insertion into viral 
DNA, thus leading to termination of the DNA 
chain and inhibiting the function of DNA 
polymerase from HBV (reverse transcriptase), 
thereby causing blockade of HBV DNA 
replication and virus propagation.[12] 
 One of the assessments of disease 
progression, choice of treatment, treatment 
response and prognosis of hepatitis B is 
quantitative HBV DNA examination. The 
presence of HBV-DNA in serum or plasma 
indicates active HBV infection and, depending 
on viral load, correlates with patient infectivity. 
The tests vary in terms of sensitivity and 
Table 3. Comparison of serum HBV DNA levels in patients with hepatitis B treated with Tenofovir and Telbivudine at 6 
months and 12 months of therapy 
Parameters 
Tenofovir (n = 8) Telbivudine (n = 26) 
OR 95%CI p-value 
Mean ± SD Mean ± SD 
Treatment 6 month 841 ± 2158 6912 ± 15176 0.44 0.10 - 1.88 0.2690 
Treatment 12 
month 
135508 ± 280580 2980 ± 7509 6.23 1.39 - 27.97 0.0170 
Note: Data are presented in mean ± SD; SD, standard deviation; OR, odd ratio; CI, confidence interval; HBV, hepatitis B virus; DNA, 
deoxyribonucleic acid. 
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standardization. These tests can be used to 
assess prognosis and guide HBV treatment.[13] 
 Mild ALT levels and low HBV DNA levels 
(eg <20,000 IU / mL for HBeAg-positive and 
<2,000 IU / mL for HBeAg-negative patients) can 
be predictors of the long-term benefit and 
safety profile of anti-HBV therapy. [14] 
In this study, the results of multiple logistic 
regression analysis showed a significant 
difference between the administration of 
Telbivudine as a hepatitis B treatment with 
lower serum HBV DNA levels compared to the 
administration of Tenofovir at the 12-month 
follow-up therapy. 
 Telbivudine is a synthetic thymidine 
nucleoside analogue with very specific antiviral 
activity for the treatment of hepatitis B virus 
(HBV), both for use alone or in combination with 
other agents in hepatitis B therapy. Di-deoxy 
telbivudine triphosphate competes with 
thymidine for insertion into viral DNA, thus 
causing DNA chain termination and inhibiting 
the function of DNA polymerase from HBV 
(reverse transcriptase). This causes a blockade 
of HBV DNA replication and virus propagation. 
[15] 
 Telbivudine inhibits HBV DNA 
polymerase (reverse transcriptase) by 
competing with a natural substrate, thymidine 
5'-triphosphate. This results in the termination 
of the DNA synthesis chain, thereby inhibiting 
viral replication. Telbivudine also inhibits the 
anticompliment or second-strand DNA. 
Telbivudine is an inhibitor of the synthesis of 
the HBV first and second chains, and shows a 
different preference for inhibiting the 
production of the second chain. [16,17] 
 Telbivudine is an effective antiviral 
treatment, and is of particular interest because 
it has higher levels of HBeAg and HBeAb 
seroconversion and potentially good effects on 
glomerular filtration levels. Seroconversion of 
HBeAg to HBeAb is considered to be a good 
prognostic predictor for HBV-GN cases. Then 
Telbivudine also exerts a protective effect on 
renal function, the serum creatinine level 
decreases and almost reaches normal, followed 
by an increase in eGFR. Even in the case of HBV-
GN, the patient's HBV DNA can decline well. At 
week 52, serum ALT levels became normal in 
patients receiving Telbivudine 400 mg, and 
Telbivudine 600 mg. [18,19] 
 Telbivudine provides lower HBV DNA 
levels followed by ALT repair reaching normal 
and improved clinical conditions with 
Telbivudine. Telbivudine is also effective for use 
in patients with kidney problems, pregnant 
women, and chronic hepatitis B. [20] 
C O N C L U S I O N  
 Telbivudine was more effective in 
lowering quantitative HBV DNA serum levels in 
patients with hepatitis B than Tenofovir with 12 
months of treatment and follow-up compared 
to 6 months of treatment. 
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